Analyses across the whole group indicated that CSF p‐tau181 was independently from tau PET associated with risk factors for AD (i.e. age and APOE ɛ4 carriership) and Aβ pathology, whereas tau PET was more strongly associated with indicators of disease progression including lower cognitive test scores and reduced cortical thickness. Here, MAPT is linked to Alzheimer disease.